Genomic alterations of Tenascin C in highly aggressive prostate cancer: a meta-analysis.

Genes Cancer · 2019 · PMC6872669 · PMID 31798767

Europe PMC DOI

hedged sentence

0.0637

closest p · 1.3× alpha

0.0637

boldest claim

The sentences

showed a trendP = 0.0637so close (0.05 < p ≤ 0.1)

This was further supported by the survival report from the TCGA dataset in which patients harboring prostate cancer with TNC alteration showed a trend of decrease in disease-free survival ( P = 0.0637), although with no difference in the overall survival that may be affected by comorbidity (Figure 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.